Medisafe Launches Outcomes-Based Partnership Model to Pharma

“Hard ROI” model is first of its kind among medication management platforms

BOSTON, MA – October 16, 2018. Medisafe, the leading digital medication management platform with nearly five million registered users worldwide, today announced the launch of a value-driven partnership model to better align interests with its life sciences partners. Under this new, data-driven model, Medisafe’s success will be linked directly to an increase in the medication adherence of its users, as measured by their prescription refills. Medisafe will continue to offer a flat SaaS license option in addition to the new variable fee approach.

Medisafe’s value-based offering stems from a comprehensive research study the company conducted together with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical development services to the life sciences industry. The study, covering multiple disease states and drug classes, shows Medisafe has a significant positive effect on the frequency of prescription refills and length of time patients remain on therapy.

Using these research findings and advanced analytics, Medisafe can predict the impact of its platform over a specified timeframe across multiple therapeutic areas and forecast revenue contributions to a given pharmaceutical brand. Medisafe is initially launching to biopharma brands in select chronic and specialty therapeutic areas. Pending additional findings from ongoing research and market response to the new offering, Medisafe plans to expand its value-driven model in the next year.

“Today’s launch is a key milestone for Medisafe. In a market that increasingly embraces value but struggles to sift through the sea of apps and their claims promising patient engagement and behavior change, healthcare stakeholders are rightfully asking for evidence that these solutions work,” says Jon Michaeli, EVP of Strategic Partnerships at Medisafe. “Medisafe now joins the ranks of the few who have proven a positive link to improved outcomes.”

Medisafe partners with pharma and life sciences in the following areas:

  • Adherence: Improving dose-level adherence for patients prescribed the brand’s medication
  • Engagement: Delivering personalized content, resources and interventions across the patient journey to keep them engaged and on therapy
  • Insights: Interpreting de-identified cohort-level behavioral trends for Medisafe users relevant to the partnership

The Medisafe team will be available this week for meetings at Digital Pharma East and the Connected Health Conference.  Click here to set up a meeting with the team at Digital Pharma East, click here to set up a meeting at the Connected Health Conference.

For more information on Medisafe, and the new value-based model, please visit the website at



You may also like

PDURS: How 7 Companies and Groups Responded to the Draft Guidelines

The FDA’s Draft Guidelines for Prescription Drug Use Related Software (PDURS) have sparked considerable discussion among various stakeholders, including pharmaceutical 

..Read More

PDURS: Insights for Pharma’s Digital Health and Innovation Teams

The FDA’s new Draft Guidelines for Prescription Drug Use Related Software (PDURS) are shaping the future of digital health in 

..Read More

PDURS: How Pharma Brand Marketing, Procurement Teams Can Prepare

As the digital health landscape evolves, pharmaceutical companies must adapt to new regulatory frameworks that ensure patient safety and product 

..Read More

Want to Learn More?

We bring decades of experience to your challenges—and technology and solutions uniquely designed to meet your needs.